HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapies HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapies

View post:
Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials

COPENHAGEN, Denmark, July 22, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that the marketing authorization for the Company’s smallpox vaccine, IMVANEX®, is extended to include protecting people from monkeypox disease.

Originally posted here:
Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Garching / Munich, July 22, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board as Chief Business Officer (CBO) of the ITM Group. Dr. Marx joined ITM in 2008 and has since contributed significantly to the company’s growth and development across various product management positions, including Head of Sales. As CBO, Dr. Marx will strengthen the company’s marketing focus as it prepares for the potential product launch of its radiopharmaceutical lead candidate, ITM-11, for the treatment of neuroendocrine tumors (GEP-NETs). In his new role, he will have overall responsibility for marketing and sales, and market access and intelligence for the company’s radioisotopes, radiodiagnostics and radiotherapeutics as well as the further expansion of its global sales partner network.

More:
ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board

Ad Hoc Announcement Pursuant to Art. 53 LR

Read the rest here:
Addex Raises $4.2 million in Equity Financing

Oryzon invests $8.1 million in R&D in the first half 2022 Oryzon invests $8.1 million in R&D in the first half 2022

See the rest here:
ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022

BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Caroline Godfrey, Ph.D., one of PepGen’s scientific co-founders, to its Scientific Advisory Board. In connection with this appointment, Dr. Godfrey leaves her position as Senior Vice President of Discovery at PepGen.

Go here to see the original:
PepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board

Basel, 22 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Vabysmo®? (faricimab) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME). Based on this recommendation, a final decision regarding the approval of Vabysmo is expected from the European Commission in the near future.

Excerpt from:
CHMP recommends EU approval of Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss

Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the posterior segment indication later in Q3 Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the posterior segment indication later in Q3

More:
Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France

MIAMI, July 22, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the appointment of David Jin as Chief Financial Officer effective August 16, 2022. Mr. Jin will also continue to serve as Head of Corporate Development.

Read the original post:
Fortress Biotech Appoints David Jin as Chief Financial Officer

NEW YORK, July 22, 2022 (GLOBE NEWSWIRE) -- Fairway Consulting Group (FCG), a leading recruiting firm focused on providing outstanding talent solutions for the pharmaceutical, biotechnology, diagnostic, and medical device industries, today announced the Company is expanding amid continued growth. In the past 8 years, FCG has nearly tripled its annual placements.

More here:
Fairway Consulting Group Announces Expansion Amid Growth

CAMBRIDGE, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that its Senior Vice President and Chief People Officer, Carla Poulson, has been named one of Savoy Magazine’s 2022 Most Influential Black Executives in Corporate America.

More:
Mersana Therapeutics Chief People Officer Carla Poulson Named One of Savoy Magazine’s 2022 Most Influential Black Executives in Corporate America

Underwriters’ full exercise of option brings gross proceeds to $264.5 million Underwriters’ full exercise of option brings gross proceeds to $264.5 million

Go here to see the original:
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional...

Conference Call to be held Wednesday July 27, at 9:00am Eastern Time Conference Call to be held Wednesday July 27, at 9:00am Eastern Time

See the rest here:
Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update

New York, NY, and Tel Aviv, ISRAEL, July 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the preprint in ResearchGate of case study #8 entitled “A Case Review: Effects of 3CL Protease Inhibitors Paxlovid® and Tollovid™ in a Patient with Chronic Long COVID” overseen by Dr. Lee Morgentaler in concert with Andrew A. Blumenthal, RN ADS of a patient who was experiencing symptoms of Post-Acute Sequelae of COVID (PASC, or “Long COVID”) for 27 months and experienced benefit with a 5-day course of Paxlovid® treatment followed by over 30 days of supplementation with 3CL protease inhibitor immune support dietary supplement Tollovid™. The pre-publication can be viewed at: https://www.researchgate.net/publication/362174359_3CL_Protease_Inhibitors_IN_Chronic_Long_Covid_A_Case_Review_Effects_of_3CL_Protease_Inhibitors_PaxlovidR_and_Tollovid_in_a_Patient_with_Chronic_Long_Covid.

Read more:
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™  Dietary Supplementation

EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its 2022 annual meeting of stockholders (the “Annual Meeting”) has been further adjourned to Friday, August 5, 2022 at 9:00 a.m. Eastern Time with respect to Proposal 4 (Authorized Share Increase), as described in Hepion’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 29, 2022 (the “Proxy Statement”).

See the original post:
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders

ORLANDO, FL, July 22, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce the appointment of Dr. Stephen “Steve” Wilson as Immune’s Chief Executive Officer (CEO), President, and interim Chief Financial Officer (CFO) effective July 19, 2022; he will continue to serve as a member of the Company’s Board of Directors.

Original post:
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer

SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic?based therapies for the prevention and treatment of disease, today announced topline data for its Phase 1b CLEAR clinical study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen.

Continue reading here:
Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

COPENHAGEN, Denmark, July 25, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission (EC) has extended the marketing authorization for the Company’s smallpox vaccine, IMVANEX® to include protection from monkeypox and disease caused by vaccinia virus. The approval, which follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) on July 22, 2022, is valid in all European Union Member States as well as in Iceland, Liechtenstein, and Norway.

Read the rest here:
Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox

Basel, July 25, 2022 – Sandoz, a global leader in generic and biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its biologics license application (BLA) for a proposed first-of-a-kind biosimilar natalizumab, developed by Polpharma Biologics.

Read the original here:
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA

HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, today announced its name change (from Pluristem Therapeutics Inc. Nasdaq: PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be harnessed for a range of fields beyond medicine, providing solutions for various areas of the life sciences. As of July 26, 2022, Pluri will begin trading on Nasdaq under the new ticker symbol “PLUR,” CUSIP number 72942G 104.

Originally posted here:
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based...